Olanzapine in male and female adolescent patients with schizophrenia and related disorders: Minor sex differences in outcomes

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 328-331

  Dittmann, Ralf W ^a   Meyer, Eberhard ^b   Freisleder, Franz Joseph ^c   Remschmidt, Helmut ^d   Mehler Wex, Claudia ^e   Junghanss, Jenny ^f   Hagenah, Ulrich ^g   Schulte Markwort, Michael ^h   Poustka, Fritz ⁱ   Schulz, Eberhard ^j   Kluge, Michael ^k   Mästele, Anneliese ^l   Wehmeier, Peter M ^l   Schmidt, Martin H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Hospital for Child and Adolescent Psychiatry and Psychotherapy   (Germany)

^c Heckscher Hospital for Child and Adolescent Psychiatry and Psychotherapy   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f Josefinum   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^h UNIVERSITY OF HAMBURG   (Germany)

ⁱ GOETHE UNIVERSITY   (Germany)

^j UNIVERSITY OF FREIBURG   (Germany)

^k MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^l LILLY DEUTSCHLAND GMBH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADOLESCENT; AMENORRHEA; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEART RATE; HEMATOLOGY; HUMAN; LETTER; LIBIDO DISORDER; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MASTALGIA; METABOLIC PARAMETERS; OUTCOME ASSESSMENT; POSITIONAL DIZZINESS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TENSION HEADACHE; WEIGHT GAIN; WELLBEING;

ADOLESCENT; BENZODIAZEPINES; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 77952373631     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dc6935     Document Type: Letter

References (20)

1. Beratis S, Gabriel J, Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr Bull. 1994;20:287-296.
2. Cawthron P, James A, Dell J, et al. Adolescent onset psychosis: a clinical and outcome study. J Child Psychol Psychiatry. 1994;35:1321-1332.
3. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology. 2003;28:1-16.
4. Taylor R, Langdon R. Understanding gender differences in schizophrenia: a review of the literature. Curr Psychiatry Rev. 2006;2:255-265.
5. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40:1113-1117.
6. Findling RL, McNamara NK, Gracious B. Pediatric uses of atypical antipsychotics. Expert Opin Pharmacother. 2000;1: 935-945.
7. Remschmidt H, Hennighausen K, Clement HW, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry. 2000;9(suppl 1):I/9YI/19.
8. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative study. Am J Psychiatry. 1997;154:457-465.
9. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomised, 8-week trial. Neuropsychopharmacology. 2004;29: 133-145.
10. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007;164: 1547-1556.
11. Dittmann RW, Junghanss J. Olanzapin in der Behandlung jugendlicher psychotischer Patienten. Psychopharmakotherapie. 2001;8:71-75.
12. Findling RL, McNamara NK, Youngstrom EA, et al. A prospective, open-label study of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2003;42:170-175.
13. Dittmann RW, Meyer E, Freisleder FJ, et al. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol. 2008;18:54-69.
14. Kryzhanovskaya L, Schulz C, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(1):60-70.
15. Kryzhanovskakaya L, Robertson-Plouch CK, Xu W, et al. The safety of olanzapine in adolescents with schizophrenia or bipolar disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry. 2009;70:e1-e12.
16. Merry SN, Werry JS. Course and prognosis. In: Remschmidt H, ed. Schizophrenia in Children and Adolescents. Cambridge, UK: Cambridge University Press; 2001:268-297.
17. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. Int Clin Psychopharmacol. 1995;10:133-138.
18. Ligjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. Acta Psychiat Scand. 1987;76:(suppl 334):84-100.
19. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across prospective comparative clinical trials. Psychoneuroendocrinology. 2003;28:69-82.
20. Glazer WM, Conley RR, Citrome L. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study. CNS Spectr. 2006;11(suppl 10):1-13.